Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

  • Did you mean: chip (53421 items)
1.

Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.

Murray J, Gulliford S, Griffin C, Wilkins A, Syndikus I, Staffurth J, Panades M, Scrase C, Parker C, Khoo V, Dean J, Mayles H, Mayles P, Thomas S, Naismith O, Mossop H, Cruickshank C, Hall E, Dearnaley D; CHHiP Investigators.

Clin Transl Radiat Oncol. 2019 Dec 31;21:77-84. doi: 10.1016/j.ctro.2019.12.006. eCollection 2020 Mar.

PMID:
32072028
2.

Derivation of dose/volume constraints for the anorectum from clinician and patient-reported outcomes in the CHHiP trial of radiotherapy fractionation.

Wilkins A, Naismith O, Brand D, Fernandez K, Hall E, Dearnaley D, Gulliford S; CHHiP Trial Management Group.

Int J Radiat Oncol Biol Phys. 2020 Jan 24. pii: S0360-3016(20)30056-0. doi: 10.1016/j.ijrobp.2020.01.003. [Epub ahead of print]

3.

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.

Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, Scrase C, Parker C, Khoo V, Dean J, Mayles H, Mayles P, Thomas S, Naismith O, Baker A, Mossop H, Cruickshank C, Hall E, Dearnaley D; CHHiP Investigators.

Radiother Oncol. 2020 Jan;142:62-71. doi: 10.1016/j.radonc.2019.10.017. Epub 2019 Nov 22.

4.

Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.

Naismith O, Mayles H, Bidmead M, Clark CH, Gulliford S, Hassan S, Khoo V, Roberts K, South C, Hall E, Dearnaley D; CHHiP Investigators.

Clin Oncol (R Coll Radiol). 2019 Sep;31(9):611-620. doi: 10.1016/j.clon.2019.05.009. Epub 2019 Jun 11.

PMID:
31201110
5.

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity.

Naismith OF, Griffin C, Syndikus I, South C, Mayles H, Mayles P, Khoo V, Scrase C, Graham J, Hassan S, Hall E, Dearnaley DP; CHHiP Investigators.

Clin Oncol (R Coll Radiol). 2019 Sep;31(9):600-610. doi: 10.1016/j.clon.2019.05.002. Epub 2019 Jun 6.

6.

Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer.

Wilkins A, Stuttle C, Hassan S, Blanchard C, Cruickshank C, Griffin C, Probert J, Corbishley CM, Parker C, Dearnaley D, Hall E.

Clin Transl Radiat Oncol. 2018 Feb 16;10:1-6. doi: 10.1016/j.ctro.2018.02.002. eCollection 2018 Mar.

7.

How will the CHHiP trial affect the future of prostate radiotherapy?

Dearnaley D, Hall E.

Expert Rev Anticancer Ther. 2018 Jul;18(7):607-609. doi: 10.1080/14737140.2018.1477595. Epub 2018 May 25. No abstract available.

PMID:
29774771
8.

The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.

Wilson JM, Dearnaley DP, Syndikus I, Khoo V, Birtle A, Bloomfield D, Choudhury A, Graham J, Ferguson C, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Rimmer Y, Scrase C, Staffurth J, Stockdale A, Cruickshank C, Griffin C, Hall E; CHHiP Investigators.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1179-1189. doi: 10.1016/j.ijrobp.2018.01.016. Epub 2018 Jan 9.

9.

Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.

Wilkins AC, Gusterson B, Szijgyarto Z, Haviland J, Griffin C, Stuttle C, Daley F, Corbishley CM, Dearnaley DP, Hall E, Somaiah N; CHHiP Trial Investigators.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):309-315. doi: 10.1016/j.ijrobp.2018.01.072. Epub 2018 Feb 3. Erratum in: Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):226.

10.

Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.

Royce TJ, Lee DH, Keum N, Permpalung N, Chiew CJ, Epstein S, Pluchino KM, D'Amico AV.

Eur Urol Focus. 2019 Jul;5(4):577-584. doi: 10.1016/j.euf.2017.10.011. Epub 2017 Dec 5. Review.

PMID:
29221876
11.

Hypofractionation trials and radiobiology of prostate cancer.

Gulliford S, Hall E, Dearnaley D.

Oncoscience. 2017 Apr 14;4(3-4):27-28. doi: 10.18632/oncoscience.347. eCollection 2017 Mar. No abstract available.

12.

The Role of Hypofractionated Radiotherapy in Prostate Cancer.

Benjamin LC, Tree AC, Dearnaley DP.

Curr Oncol Rep. 2017 Apr;19(4):30. doi: 10.1007/s11912-017-0584-7. Review.

13.

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results.

Dearnaley D, Hall E.

Transl Androl Urol. 2017 Feb;6(1):134-136. doi: 10.21037/tau.2017.01.05. No abstract available.

15.

Response to: Sivanandan et al. Prostate Hypofractionated Radiotherapy Trial Results Need to be Interpreted with Caution due to Undertreatment of the Control Arm in the CHHiP Trial.

Dearnaley D, Syndikus I, Hall E, Gulliford S.

Clin Oncol (R Coll Radiol). 2016 Dec;28(12):798-799. doi: 10.1016/j.clon.2016.09.002. Epub 2016 Sep 15. No abstract available.

PMID:
27640308
16.

Prostate Hypofractionated Radiotherapy Trial Results Need to be Interpreted with Caution due to Undertreatment of the Control Arm in the CHHiP Trial.

Sivanandan MA, Walker G, Sundar S.

Clin Oncol (R Coll Radiol). 2016 Dec;28(12):797. doi: 10.1016/j.clon.2016.08.008. Epub 2016 Aug 31. No abstract available.

PMID:
27591001
17.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators.

Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Erratum in: Lancet Oncol. 2016 Aug;17 (8):e321.

18.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E.

Lancet Oncol. 2015 Dec;16(16):1605-16. doi: 10.1016/S1470-2045(15)00280-6. Epub 2015 Oct 28.

19.

Letter in response to the Wedlake et al. paper 'Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies'.

Dearnaley D, Griffin CL, Hall E; CHHiP Trial Management Group.

Eur J Cancer. 2013 May;49(7):1783-6. doi: 10.1016/j.ejca.2012.12.029. Epub 2013 Feb 26. No abstract available.

PMID:
23452989
20.

Tomotherapy-like versus VMAT-like treatments: a multicriteria comparison for a prostate geometry.

Pardo-Montero J, Fenwick JD.

Med Phys. 2012 Dec;39(12):7418-29. doi: 10.1118/1.4768159.

PMID:
23231292
  • Did you mean: chip (53421 items)

Supplemental Content

Loading ...
Support Center